GlassScriptPhysician profile
Daniel L Rasor
NPI 1043211329
$16,531.68
in general payments reported to CMS, 2019-2025
52 companies · $3,893 in 2025
The $3,893 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $2,333 · 2021: $2,946 · 2022: $2,507 · 2023: $2,009 · 2024: $1,990 · 2025: $3,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,873 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,872.57 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,112.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,107.54 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,582.78 | 2019-2025 | Zepbound, Kisunla, Jardiance |
| Amgen INC. | $1,401.57 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $1,278.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,050.78 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $822.58 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $691.05 | 2022-2025 | |
| Pfizer INC. | $647.80 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $508.34 | 2019-2025 | Spravato |
| Gilead Sciences, INC. | $356.91 | 2019-2024 | |
| Corcept Therapeutics | $353.08 | 2021-2025 | Korlym |
| Amarin Pharma, INC. | $344.89 | 2019-2022 | |
| Allergan, INC. | $296.35 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $250.77 | 2021-2025 | Zoryve, Livalo, Seglentis |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rasor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.